•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness
Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients
Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock
Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets
Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
What's Going On With Bluejay Diagnostics Shares On Wednesday?
Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
Bluejay Diagnostics Provides First Quarter 2026 Corporate Update
Critical Contrast: Bluejay Diagnostics (NASDAQ:BJDX) & STERIS (NYSE:STE)
Reviewing Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Bluejay Diagnostics (NASDAQ:BJDX)
Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial
Comparing Coloplast A/S (OTCMKTS:CLPBY) & Bluejay Diagnostics (NASDAQ:BJDX)
Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics
Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised
Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026
Bluejay Diagnostics (NASDAQ:BJDX) Trading 0.1% Higher – What’s Next?